Basket of garlic

Could a garlic compound provide an anti-aging boost for humans? (Photo by team voyas on Unsplash)

Scientists Found a Compound in Garlic That Strengthened Aging Muscles in Mice. The Route It Takes Is the Surprising Part.

In a Nutshell

  • A compound found in aged garlic extract triggered a chain reaction in fat tissue that boosted a key energy-regulating protein in the blood of both mice and middle-aged humans.
  • In aged mice treated long-term with this garlic compound, muscle strength improved and overall frailty scores dropped.
  • The garlic compound appears to work by sending signals from fat tissue to the brain, which then communicates with muscles through the nervous system.
  • Participants in the underweight range did not show the same blood protein response, suggesting the compound depends on a minimum level of fat tissue to function.

Losing muscle strength is one of the quietest crises of aging — and one of the most consequential. It’s what turns a stumble into a fall, and a fall into a lost independence. Researchers think a compound hiding in aged garlic may be worth watching as one piece of the solution, and the biological route it takes to get there is unlike anything scientists expected.

Researchers at Washington University and collaborating institutions in Japan found that a sulfur-containing compound called S-1-propenyl-L-cysteine, or S1PC, found in aged garlic extract, sets off a chain reaction in fat tissue that eventually signals the brain to help preserve muscle strength in aging mice. In middle-aged people given a single dose, S1PC raised blood levels of a key protein tied to this process. hough whether that translates into stronger muscles over time remains an open question.

Published in Cell Metabolism, the findings suggest something as simple as a garlic-derived molecule might one day be part of a strategy for fighting one of aging’s most debilitating consequences.

What makes the pathway so unexpected is where it starts. Rather than acting on muscle directly, S1PC appears to work through fat tissue, triggering a molecular signal that travels to the brain, which then communicates with muscles through the nervous system. Researchers have been searching for ways to slow that muscle decline through drugs, lifestyle changes, or compounds found in nature. This garlic study adds an unexpected contender to that search.

How the Garlic Compound Triggers a Chain Reaction From Fat to Brain to Muscle

At the center of this discovery is a protein called eNAMPT, an enzyme involved in producing a molecule the body uses as fuel at the cellular level, known as NAD+. NAD+ works like a biological battery charge: cells need it to function properly, and levels tend to fall as people age. Prior research had shown that eNAMPT circulates in the blood and plays a key role in keeping NAD+ levels up in various tissues, including the brain.

What the research team found is that S1PC, after being absorbed into the body, makes its way quickly to fat tissue, specifically white fat, where it activates a protein called LKB1. LKB1 acts like a master switch inside cells, and when S1PC turns it on, it sets off a cascade that ends with fat cells releasing more eNAMPT into the bloodstream. Researchers confirmed this in laboratory cell experiments and in mice.

Scientists also traced where that released eNAMPT actually goes. Using a tracking method that involved tagging the protein with a molecular flag and following it through the body, they found that eNAMPT released from fat tissue reaches the hypothalamus, a small but powerful region deep in the brain that regulates everything from body temperature to metabolism. No eNAMPT showed up in skeletal muscle directly. Instead, the hypothalamus appears to act as a relay station, sending signals through the nervous system that then reach the muscles.

Garlic muscle study infographic
(Image generated by StudyFinds)

What Happened to the Mice Treated With the Garlic Compound

To see whether this molecular chain translated into real physical benefits, researchers gave aged mice S1PC daily, either mixing it into their food or dissolving it in their drinking water. They did this for eight months, starting when the animals were the equivalent of late middle age. Results followed.

Mice that received S1PC showed measurable improvements in muscle force during electrical stimulation tests, compared to untreated mice of the same age. Their overall frailty scores improved, and their body temperatures, which tend to drop in older mice and can signal metabolic decline, were restored closer to levels seen in younger animals. Grip strength improved as well. Muscle size did not change, suggesting the benefit came from how the muscle was functioning, not from building more tissue.

Inside those muscles, researchers found higher levels of a receptor that responds to signals from the nervous system, as well as increased activity of a protein that marks those signals being received. When they blocked that signaling pathway with a drug before giving S1PC, the muscle-related effects were essentially wiped out — strong evidence, in mice, that the nervous system connection was the real mechanism at work.

Scientists also tested what happens when fat tissue cannot produce eNAMPT at all, using a specially engineered group of mice. Those animals showed significantly reduced muscle force, reinforcing the idea that fat-derived eNAMPT genuinely matters for muscle health.

The Human Data: Signs That S1PC Works Beyond Mice

Mouse studies are a necessary first step, but the researchers also wanted to see whether S1PC could raise eNAMPT levels in people. They recruited 44 healthy Japanese adults between the ages of 20 and 49 and administered either S1PC, delivered through a highly concentrated garlic powder containing 17% S1PC, or a placebo. Four individuals withdrew, leaving 21 in the placebo group and 19 in the S1PC group. Critically, each participant received only a single dose — so this was a short-term blood-marker study, not a test of muscle strength or frailty over time.

After a single dose of 25 mg of S1PC, blood levels of S1PC rose quickly in both men and women. Among participants aged 40 and older who had healthy levels of body fat, those who received S1PC showed a meaningful increase in circulating eNAMPT levels at the 120-minute mark, while the placebo group did not. Participants who were significantly underweight did not show the same effect, which the researchers say makes sense: if someone has very little fat tissue to begin with, there may not be enough of it to respond to S1PC’s signaling.

S1PC did not appear to trigger fat breakdown in humans, which suggests the compound targets a very specific molecular pathway in fat cells rather than broadly disrupting how they work.

A New Role for an Ancient Ingredient

Perhaps the most unexpected aspect of the study is what S1PC does (and doesn’t do) at the molecular level. When LKB1 is activated in cells, it typically also activates another well-known protein called AMPK, which is involved in energy regulation. S1PC appears to activate LKB1 in a way that bypasses AMPK entirely, targeting instead the specific pathway that leads to eNAMPT secretion. Researchers found that S1PC seems to act almost like a biological glue, helping key proteins assemble into a complex that activates LKB1. This kind of targeted action could matter greatly for researchers looking to design future compounds with similar or improved effects.

Several open questions remain: it is still not clear which specific brain cells respond to eNAMPT, whether the effects differ between men and women, or whether long-term use in humans produces the same muscle benefits seen in mice. Those questions will need to be answered in future studies, including clinical trials that track muscle function over time, not just blood protein levels.

Researchers identified a specific compound, traced a specific molecular mechanism across fat tissue, the brain, and muscles, and observed real functional improvements in aged animals. That kind of specificity can move a field forward.

Garlic has always had its enthusiasts. Now science may be giving those ancient claims a precise biological explanation.

Disclaimer: This article is based on peer-reviewed research published in Cell Metabolism (June 2, 2026). The research was funded under a sponsored research agreement between the Institute for Research on Productive Aging and Wakunaga Pharmaceutical Co., Ltd., the maker of aged garlic extract products. Lead author Shin-ichiro Imai holds financial relationships with entities related to this research, including patent-licensing fees and leadership roles at affiliated organizations. These disclosures were reviewed by Washington University’s Conflict of Interest Committee. This article is intended for general informational purposes only and should not be taken as medical advice.


Paper Notes

Limitations

Researchers flag several meaningful gaps. It remains unclear exactly which neurons in the hypothalamus respond to the eNAMPT-containing particles released from fat tissue. The study also cannot rule out additional mechanisms — beyond the fat-to-brain signaling pathway — that might explain the long-term muscle improvements seen in mice. Potential differences between male and female responses to S1PC were not fully examined; the animal experiments primarily used male mice to reduce variability associated with the reproductive cycle in females. Most significantly, the human portion of the study involved only a single dose of S1PC, so the effect on actual muscle function in people following long-term use has not yet been tested and will require future investigation.

Funding and Disclosures

This research was carried out under a sponsored research agreement between the Institute for Research on Productive Aging (IRPA) and Wakunaga Pharmaceutical Co., Ltd. Lead author Shin-ichiro Imai receives a portion of patent-licensing fees from MetroBiotech and the IRPA through Washington University, serves as Chairman of the IRPA, and is a co-CEO of LongGen Bioscience. These potential conflicts of interest have been disclosed to and reviewed by the Washington University Conflict of Interest Committee. Based on this study’s results, the IRPA and Wakunaga Pharmaceutical Co., Ltd. have jointly filed a provisional patent in the United States (patent application no. 63/796,082). The term “S1PC” has been registered as a trademark of Wakunaga Holdings Co., Ltd. in the United States and Japan.

Publication Details

Authors: Jun-ichiro Suzuki, Kiyoshi Yoshioka, Masahiro Kurita, Takumi Sugimoto, Takahiro Eguchi, Naoki Ito, Aoi Kodama, Yasutomi Kamei, Masahiro Ohtani, Toshiaki Matsutomo, and Shin-ichiro Imai. Authors are affiliated with Wakunaga Pharmaceutical Co., Ltd. (Hiroshima, Japan); the Institute for Research on Productive Aging (Tokyo, Japan); the National Center for Geriatrics and Gerontology (Obu, Japan); Kyoto Prefectural University (Kyoto, Japan); and Washington University School of Medicine (St. Louis, MO, USA).

Journal: Cell Metabolism, Volume 38, June 2, 2026

Paper Title: “Garlic-derived metabolite activates LKB1, promotes adipose eNAMPT secretion, and improves age-related muscle function via hypothalamic signaling”

DOI: 10.1016/j.cmet.2026.04.006

About StudyFinds Analysis

Called "brilliant," "fantastic," and "spot on" by scientists and researchers, our acclaimed StudyFinds Analysis articles are created using an exclusive AI-based model with complete human oversight by the StudyFinds Editorial Team. For these articles, we use an unparalleled LLM process across multiple systems to analyze entire journal papers, extract data, and create accurate, accessible content. Our writing and editing team proofreads and polishes each and every article before publishing. With recent studies showing that artificial intelligence can interpret scientific research as well as (or even better) than field experts and specialists, StudyFinds was among the earliest to adopt and test this technology before approving its widespread use on our site. We stand by our practice and continuously update our processes to ensure the very highest level of accuracy. Read our AI Policy (link below) for more information.

Our Editorial Process

StudyFinds publishes digestible, agenda-free, transparent research summaries that are intended to inform the reader as well as stir civil, educated debate. We do not agree nor disagree with any of the studies we post, rather, we encourage our readers to debate the veracity of the findings themselves. All articles published on StudyFinds are vetted by our editors prior to publication and include links back to the source or corresponding journal article, if possible.

Our Editorial Team

Steve Fink

Editor-in-Chief

John Anderer

Associate Editor

Leave a Comment